See more : Findi Limited (FND.AX) Income Statement Analysis – Financial Results
Complete financial analysis of ANI Pharmaceuticals, Inc. (ANIP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ANI Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Reliance Capital Limited (RELCAPITAL.NS) Income Statement Analysis – Financial Results
- Saurashtra Cement Limited (SAURASHCEM.BO) Income Statement Analysis – Financial Results
- Cloudera, Inc. (0I0N.L) Income Statement Analysis – Financial Results
- Rusoro Mining Ltd. (RMLFF) Income Statement Analysis – Financial Results
- PT Asuransi Tugu Pratama Indonesia Tbk (TUGU.JK) Income Statement Analysis – Financial Results
ANI Pharmaceuticals, Inc. (ANIP)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.anipharmaceuticals.com
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 486.82M | 316.39M | 216.14M | 208.48M | 206.55M | 201.58M | 176.84M | 128.62M | 76.32M | 55.97M | 30.08M | 2.30M | 435.16K | 2.47M | 1.26M | 3.78M | 493.05K | 14.44M | 258.35K | 77.89K | 65.49K | 2.83M | 1.75M | 2.00 | 1.00 | 123.06K |
| Cost of Revenue | 181.51M | 138.79M | 100.61M | 87.16M | 63.15M | 73.02M | 79.03M | 48.78M | 12.69M | 11.47M | 9.97M | 9.17M | 50.00K | 268.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -24.29K | 0.00 | 0.00 |
| Gross Profit | 305.30M | 177.60M | 115.53M | 121.32M | 143.39M | 128.55M | 97.81M | 79.84M | 63.63M | 44.50M | 20.11M | -6.87M | 385.16K | 2.21M | 1.26M | 3.78M | 493.05K | 14.44M | 258.35K | 77.89K | 65.49K | 2.83M | 1.75M | 24.29K | 1.00 | 123.06K |
| Gross Profit Ratio | 62.71% | 56.13% | 53.45% | 58.19% | 69.42% | 63.77% | 55.31% | 62.07% | 83.37% | 79.50% | 66.84% | -298.44% | 88.51% | 89.14% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 1,214,600.00% | 100.00% | 100.00% |
| Research & Development | 34.29M | 22.32M | 11.37M | 16.00M | 19.81M | 15.39M | 9.07M | 2.91M | 2.87M | 2.68M | 1.71M | 16.89M | 44.18M | 39.71M | 13.68M | 15.79M | 4.75M | 3.86M | 6.41M | 9.16M | 3.69M | 4.79M | 2.14M | 1.89M | 660.59K | 1.40M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.06M | 31.58M | 27.83M | 21.16M | 17.94M | 16.39M | 8.23M | 6.98M | 5.94M | 5.67M | 5.96M | 4.33M | 7.03M | 3.05M | 3.08M | 2.33M | 1.77M | 2.30M | 1.68M | 853.39K | 1.11M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 161.70M | 124.04M | 84.29M | 64.99M | 55.84M | 44.06M | 31.58M | 27.83M | 21.16M | 17.94M | 16.39M | 8.23M | 6.98M | 5.94M | 5.67M | 5.96M | 4.33M | 7.03M | 3.05M | 3.08M | 2.33M | 1.77M | 2.30M | 1.68M | 853.39K | 1.11M |
| Other Expenses | 62.35M | 56.97M | 48.03M | 55.90M | 51.32M | -550.00K | 55.00K | -74.00K | 41.00K | 160.00K | -305.00K | 353.95K | 148.24K | 167.99K | 20.33M | 43.14K | 89.82K | 117.78K | 100.94K | 101.94K | 92.93K | 92.10K | 92.56K | 122.79K | 90.97K | 269.70K |
| Operating Expenses | 258.33M | 203.33M | 143.70M | 136.89M | 126.97M | 93.19M | 68.58M | 53.08M | 30.93M | 24.49M | 19.21M | 25.47M | 51.31M | 45.81M | 39.68M | 21.79M | 9.17M | 11.00M | 9.56M | 12.34M | 6.11M | 6.64M | 4.53M | 3.69M | 1.60M | 2.78M |
| Cost & Expenses | 439.85M | 342.12M | 244.31M | 224.05M | 190.12M | 166.22M | 147.61M | 101.86M | 43.62M | 35.96M | 29.18M | 25.47M | 51.36M | 46.08M | 39.68M | 21.79M | 9.17M | 11.00M | 9.56M | 12.34M | 6.11M | 6.64M | 4.53M | 3.66M | 1.60M | 2.78M |
| Interest Income | 0.00 | 28.05M | 11.92M | 9.45M | 12.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.54K | 8.33K | 12.67K | 11.65K | 588.46K | 1.10M | 428.34K | 401.19K | 250.42K | 86.59K | 63.79K | 174.42K | 227.72K | 0.00 | 0.00 |
| Interest Expense | 26.94M | 28.05M | 11.92M | 9.45M | 12.97M | 14.76M | 12.04M | 11.33M | 11.01M | 787.00K | 467.00K | 348.02K | 681.57K | 688.08K | 147.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 59.79M | 56.97M | 47.25M | 44.64M | 44.61M | 33.74M | 27.93M | 22.34M | 6.90M | 3.88M | 1.11M | 258.95K | 148.24K | 167.99K | 137.28K | 43.14K | 89.82K | 117.78K | 100.94K | 101.94K | 92.93K | 92.10K | 110.56K | 122.79K | 90.97K | 139.77K |
| EBITDA | 106.60M | 48.07M | -1.68M | 29.07M | 60.74M | 69.10M | 57.16M | 56.31M | 39.64M | 24.04M | 7.51M | -27.23M | -50.78M | -45.34M | -47.24M | -17.38M | -7.49M | 3.56M | -9.55M | -11.91M | -5.95M | -3.72M | -2.68M | -3.31M | -1.51M | -2.52M |
| EBITDA Ratio | 21.90% | 10.09% | 6.82% | 13.71% | 29.44% | 34.01% | 32.35% | 38.12% | 51.94% | 42.96% | 5.66% | -995.51% | -11,667.01% | -1,678.41% | -2,330.70% | -475.31% | -1,742.13% | 32.10% | -3,271.24% | -15,618.58% | -9,089.41% | -131.22% | -153.10% | -177,106,050.00% | -151,397,600.00% | -2,047.48% |
| Operating Income | 46.97M | -25.06M | -32.51M | -16.06M | 16.35M | 35.36M | 28.33M | 20.08M | 32.70M | 20.01M | 898.00K | -23.17M | -50.93M | -43.61M | -38.43M | -18.01M | -8.68M | 3.44M | -9.30M | -12.27M | -6.05M | -3.81M | -2.79M | -3.66M | -1.60M | -2.66M |
| Operating Income Ratio | 9.65% | -7.92% | -15.04% | -7.71% | 7.92% | 17.54% | 16.02% | 15.61% | 42.84% | 35.74% | 2.99% | -1,007.14% | -11,703.01% | -1,762.50% | -3,054.36% | -476.45% | -1,760.34% | 23.82% | -3,600.61% | -15,749.47% | -9,231.29% | -134.47% | -159.43% | -183,245,550.00% | -160,494,100.00% | -2,161.05% |
| Total Other Income/Expenses | -27.10M | -27.38M | -16.27M | -9.95M | -13.19M | -15.31M | -11.98M | -11.40M | -10.97M | -627.00K | -772.00K | -5.60M | -681.67K | -2.59M | -9.10M | -17.41B | -7.58B | -1.08M | -348.81K | 250.42K | 86.59K | 0.00 | 174.42K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 19.87M | -62.67M | -56.06M | -25.96M | 3.16M | 20.05M | 16.35M | 8.68M | 21.73M | 19.38M | 126.00K | -27.84M | -51.61B | -46.20B | -47.53B | -17.43B | -7.58B | 2.79B | -9.65B | -12.02M | -5.96M | -3.81M | -2.61M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 4.08% | -19.81% | -25.94% | -12.45% | 1.53% | 9.95% | 9.24% | 6.75% | 28.48% | 34.62% | 0.42% | -1,210.03% | -11,859,661.73% | -1,867,089.37% | -3,777,879.80% | -460,882.47% | -1,538,256.46% | 19,331.99% | -3,735,629.43% | -15,427.94% | -9,099.08% | -134.47% | -149.44% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.09M | -14.77M | -13.46M | -3.41M | -2.94M | 4.56M | 17.43M | 4.74M | 6.36M | -9.37M | 20.00K | -121.79K | 681.67K | 2.59M | 9.10M | -17.41B | -7.58B | 648.49K | 348.81K | 0.00 | 0.00 | 0.00 | 0.00 | -227.72K | -198.68K | 0.00 |
| Net Income | 18.78M | -47.90M | -42.60M | -22.55M | 6.09M | 15.49M | -1.08M | 3.93M | 15.38M | 28.75M | 301.00K | -27.72M | -51.61M | -46.20M | -47.53M | -17.43M | -7.58M | 2.79M | -9.65M | -12.02M | -5.96M | -3.81M | -2.61M | -3.44M | -1.41M | -2.66M |
| Net Income Ratio | 3.86% | -15.14% | -19.71% | -10.82% | 2.95% | 7.69% | -0.61% | 3.06% | 20.14% | 51.36% | 1.00% | -1,204.73% | -11,859.66% | -1,867.09% | -3,777.88% | -460.88% | -1,538.26% | 19.33% | -3,735.63% | -15,427.94% | -9,099.08% | -134.47% | -149.44% | -171,859,750.00% | -140,625,900.00% | -2,161.05% |
| EPS | 0.95 | -2.95 | -3.38 | -1.88 | 0.51 | 1.33 | -0.09 | 0.34 | 1.34 | 2.61 | -0.92 | -7.64 | -18.88 | -25.23 | -50.39 | -22.97 | -10.71 | 4.68 | -17.92 | -25.23 | -19.44 | -18.28 | -14.50 | -21.51 | -10.24 | -27.47 |
| EPS Diluted | 0.94 | -2.95 | -3.38 | -1.88 | 0.50 | 1.32 | -0.09 | 0.34 | 1.32 | 2.59 | -0.92 | -7.64 | -18.88 | -25.23 | -50.39 | -22.97 | -10.71 | 4.68 | -17.92 | -25.23 | -19.44 | -18.28 | -14.50 | -21.51 | -10.24 | -27.47 |
| Weighted Avg Shares Out | 18.00M | 16.26M | 12.60M | 11.96M | 11.84M | 11.68M | 11.55M | 11.45M | 11.37M | 10.94M | 5.07M | 3.63M | 2.73M | 1.83M | 943.11K | 758.54K | 707.93K | 588.64K | 538.67K | 476.26K | 306.63K | 208.42K | 180.15K | 159.82K | 137.29K | 96.83K |
| Weighted Avg Shares Out (Dil) | 18.19M | 16.26M | 12.60M | 11.96M | 12.04M | 11.77M | 11.55M | 11.57M | 11.56M | 11.05M | 5.07M | 3.63M | 2.73M | 1.83M | 943.11K | 758.54K | 707.93K | 596.78K | 538.67K | 476.26K | 306.63K | 208.42K | 180.15K | 159.82K | 137.29K | 96.83K |
ANI Pharmaceuticals, Inc. (ANIP) Q2 2024 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO...
ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the pricing of its offering of $275,000,000 aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a...
ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced its intention to offer, subject to market and other conditions, $250,000,000 aggregate principal amount of convertible senior notes due 2029 (the...
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $1.28 per share a year ago.
ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance
BAUDETTE, Minn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the three months ended June 30, 2024.
Seeking Clues to ANI (ANIP) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for ANI (ANIP), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
ANIP has three 505(b)(2) NDA submissions under FDA review, including oral liquid terazosin, female testosterone drug, and oral liquid hydrochlorothiazide. Potential peak sales for Tezruly and hydrochlorothiazide in the US could exceed $500 million, while the female testosterone drug could...
ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release...
Source: https://incomestatements.info
Category: Stock Reports